Press Release – Global COPD and Asthma Devices Market
11/14/2016

Global COPD & Asthma Devices Market to reach $27,465.1 Millions by 2022, growing at a CAGR of 5.2% during 2016 - 2022

Online PR News – 14-November-2016 – uttar pradesh – Global COPD & Asthma Devices Market to reach $27,465.1 Millions by 2022, growing at a CAGR of 5.2% during 2016 - 2022
According to a recently published report by KBV Research, the Global COPD and Asthma Devices Market attained a market size of $ 27,465.1 Million in 2015 and is expected to reach $ 39,051.4 Million by 2022 growing at a CAGR of 5.2 % CAGR during 2016 - 2022. The Asia Pacific market dominated the Global COPD and Asthma Devices Market in 2015 and would continue till 2022, growing at a CAGR of 6.5% during the forecast period. The Europe market is expected to reach a market size of $ 7,419.8 Million by 2022. The North America market would witness the high growth rate of 3.3 % during 2016-2022.

The Metered Dose Inhalers (MDIs) market dominated the Global COPD & Asthma Inhaler Market in 2015 and would continue till 2022 growing at a CAGR of 4.2 % during the forecast period. The Soft Mist Inhalers (SMIs) market is expected to reach a market size of $ 10,663.1 Million by 2022. The Dry Powder Inhalers (DPIs) market would witness the high growth rate of 7.4 % during 2016-2022.

The US market dominated the North America COPD & Asthma Metered Dose Inhalers (MDIs) Market in 2015 and would continue till 2022. The Canada market would witness the growth rate of 3.7% during 2016-2022.
The report highlights the adoption of COPD & Asthma Devices worldwide. Based on the product type; the market is segmented into Inhalers and Nebulizers market. Further the Inhaler segment is sub segmented into Dry Powder Inhalers, Metered Dose Inhalers and Soft Mist Inhalers Market. The Nebulizers segment is bifurcated into Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers Market. The geographies included in the report are North America, Europe, Asia Pacific and LAMEA (Latin America, Middle East and Africa).
Key players profiled in the report include Glaxosmithcline PLC., Novartis International AG., Biotronik SE & Co. KG., AstraZeneca Plc., 3M Healthcare, GF Health Products, Inc., Sunovion Pharmaceuticals Inc., Smith Medicals, Inc., Baxter International and Philips.

Press Release – North America COPD & Asthma Devices Market
North America COPD & Asthma Devices Market to reach $7,039.1 Million by 2022, growing at a CAGR of 3.3% during 2016-2022
According to a recently published report by KBV Research, the North America COPD & Asthma Device Market attained a market size of $7,039.1 Million in 2015 and is expected to reach $8,786.6 Million by 2022 growing at a CAGR of 3.3% CAGR during 2016 - 2022.

The US market dominated the North America COPD & Asthma Device Market in 2015 and would continue till 2022, growing at a CAGR of 2.5% during the forecast period. The Canada market is expected to reach a market size of $1,318.0 Million by 2022. The Mexico market would witness the high growth rate of 7.6% during 2016-2022.
The Pneumatic Nebulizers market dominated the North America COPD & Asthma Nebulizer Market in 2015 and would continue till 2022 thereby achieving a market value of $942.8 Million by 2022 growing at a CAGR of 3.2% during the forecast period. The Mesh Nebulizer market would witness the high growth rate of 3.2% during 2016-2022.
The report highlights the adoption of COPD & Asthma Devices in North America. Based on the product type; the market is segmented into Inhalers and Nebulizers market. Further the Inhaler segment is sub segmented into Dry Powder Inhalers, Metered Dose Inhalers and Soft Mist Inhalers Market. The Nebulizers segment is bifurcated into Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers Market. The countries included in the report are U.S, Canada, Mexico and Rest of North America.
Key players profiled in the report include Glaxosmithcline PLC., Novartis International AG., Biotronik SE & Co. KG., AstraZeneca Plc., 3M Healthcare, GF Health Products, Inc., Sunovion Pharmaceuticals Inc., Smith Medicals, Inc., Baxter International and Philips.
Press Release – Europe COPD & Asthma Devices Market
Europe COPD & Asthma Devices Market to reach $5,522.2 Million by 2022, growing at a CAGR of 4.4% during 2016-2022
According to a recently published report by KBV Research, the Europe COPD & Asthma Device Market attained a market size of $ 5,522.2 Million in 2015 and is expected to reach $ 7,419.8 Million by 2022 growing at a CAGR of 4.4 % CAGR during 2016 - 2022.
The Russia market dominated the Europe COPD & Asthma Device Market in 2015 and would continue till 2022 growing at a CAGR of 2.7 % during the forecast period. The Germany market is expected to reach a market size of $ 1,246.5 Million by 2022. The UK market would witness the high growth rate of 5.4 % during 2016-2022.
The Inhalers market dominated the Russia COPD and Asthma Devices Market in 2015 and would continue till 2022 thereby achieving a market value of $ 1,553.6 Million by 2022 growing at a CAGR of 2.8 % during the forecast period.
The report highlights the adoption of COPD & Asthma Devices in Europe. Based on the product type; the market is segmented into Inhalers and Nebulizers market. Further the Inhaler segment is sub segmented into Dry Powder Inhalers, Metered Dose Inhalers and Soft Mist Inhalers Market. The Nebulizers segment is bifurcated into Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers Market. The Countries included in the report are Russia, Germany, UK, France, Spain, Italy and Rest of Europe.
Key players profiled in the report include Glaxosmithcline PLC., Novartis International AG., Biotronik SE & Co. KG., AstraZeneca Plc., 3M Healthcare, GF Health Products, Inc., Sunovion Pharmaceuticals Inc., Smith Medicals, Inc., Baxter International and Philips.
Press release – Asia Pacific COPD & Asthma Devices Market
Asia Pacific COPD & Asthma Device Market to reach $15,893.9 Million by 2022, growing at a CAGR of 6.5% during 2016-2022
According to a recently published report by KBV Research, the Asia Pacific COPD & Asthma Device Market attained a market size of $ 10,267.8 Million in 2015 and is expected to reach $ 15,893.9 Million by 2022 growing at a CAGR of 6.5 % CAGR during 2016 - 2022.
The Metered Dose Inhalers (MDIs) market dominated the Asia Pacific COPD & Asthma Inhaler Market in 2015 and would continue till 2022, growing at a CAGR of 5.4 % during the forecast period. The Soft Mist Inhalers (SMIs) market is expected to reach a market size of $4,339.9 Million by 2022. The Dry Powder Inhalers (DPIs) market would witness the high growth rate of 8.7 % during 2016-2022.
The China market is expected to continue its dominance thereby growing at a CAGR of 7.0 % during the forecast period. The Japan market is expected to reach a market size of $ 1,796.0 Million by 2022. The India market would witness the high growth rate of 8.5 % during 2016-2022.
The report highlights the adoption of COPD & Asthma Devices in Asia Pacific. Based on the product type; the market is segmented into Inhalers and Nebulizers market. Further the Inhaler segment is sub segmented into Dry Powder Inhalers, Metered Dose Inhalers and Soft Mist Inhalers Market. The Nebulizers segment is bifurcated into Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers Market. The countries included in the report are Germany, UK, France, Russia, Spain, Italy and Rest of Asia Pacific.
Key players profiled in the report include Glaxosmithcline PLC., Novartis International AG., Biotronik SE & Co. KG., AstraZeneca Plc., 3M Healthcare, GF Health Products, Inc., Sunovion Pharmaceuticals Inc., Smith Medicals, Inc., Baxter International and Philips.